Business Wire

Seoul Semiconductor: Philips Lighting Products Ordered to Recall 7-Year-Old Items

Share

The German District Court of Düsseldorf, on November 19 ruled in favor of Seoul Semiconductor (KOSDAQ:046890) in the patent infringement lawsuits, and also ordered that products manufactured by Philips Lighting and sold since March 2017 be recalled and destroyed. The Court also ruled that a fine of up to €250,000 would be imposed for each violation of this order. On December 17, the German Federal Patent Court also affirmed the validity of these patents, which solidifies the strength of many related patents.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241225151382/en/

Application Examples with CRI 70 or Higher (Photo: Seoul Semiconductor)

These court orders relate to the core technology used to achieve CRI 70 (Color Rendering Index 70%) or higher, applicable to all home lighting, automotive lighting products, IT flash, and backlights. Since the effects of these judgments are applicable to all products infringing on the patented technology, it is expected to have a ripple effect on markets worth over $100 billion for finished goods and over $10 billion for packages in the lighting, automotive, and IT sectors.

Philips Lighting brand (currently Signify Group) is the world’s leading lighting company with 2023 annual revenue of approximately $7 billion. The Court ordered Conrad Electronic, the global distributor where these products are sold, to immediately cease the sale of certain products manufactured by affiliates of Philips Lighting brand, and also ordered the recall and destruction of infringing products distributed in the market since March 29, 2017. Additionally, the Court ruled that a fine of up to €250,000 per violation would be imposed for each non-compliance. This serves as a strong punitive measure to prevent the recurrence of such infringement activities. These court orders are applicable to all products with a CRI of 70 or higher, not just those manufactured by the affiliates of Philips Lighting brand. Particularly, by defeating the invalidation lawsuit filed by Philips Lighting, Seoul Semiconductor has strengthened the related patent technology.

For the past 30 years, Seoul Semiconductor has been pursuing its vision of "clean, healthy, and beautiful with light," striving to shift the paradigm from harmful artificial lighting to the light of nature. To achieve this, the company invests nearly $100 million annually, about 10% of its revenue, in research and development (R&D). As a result, Seoul Semiconductor holds an overwhelming number of over 18,000 optoelectronic patents in the LED industry and has collaborated with Mitsubishi Chemical Corporation (MCC) for years on joint research and development to improve CRI.

Chung Hoon Lee, Seoul’s founder and CEO said, “Infringement of intellectual property causes frustration among young entrepreneurs and innovative companies.” He added, “Our investment in preventing technology theft helps to create a fairer market and encourages young people and companies around the world to continue innovating, helping all of us contribute to a better world. This aligns with one of our company's three core missions: honor, trust, and contribution.”

About Seoul Semiconductor

Seoul Semiconductor is the world's third-largest global opto semiconductor (LED) company that has focused solely on LEDs for the past 30 years. Under the vision of "Make the world clean, healthy and beautiful with light" Seoul Semiconductor leads the new paradigm of light with world-first technologies in the fields of lighting, automotive, and IT (backlighting), while Seoul Viosys, a subsidiary, is at the forefront of MicroLED, UV, sensors, and Dacom.

Notable world-first technologies include the innovative no-wire LED "WICOP"; "SunLike," which replicates the full spectrum of natural sunlight; the high-voltage LED "Acrich"; the ultra-bright "nPola" LED, which is more than 10 times brighter than traditional LEDs; the RGB one-chip MicroLED "WICOP Pixel"; and the UV cleaning technology "Violeds."

Seoul Semiconductor holds an overwhelming 18,000 patents in the industry and has won over 100 patent litigations across eight countries in the past 20 years. Believing that the patent system offers hope to young people and serves as a stepping stone to a better world, the company actively engages in intellectual property protection activities. For more details, please visit our official websites (http://www.seoulsemicon.com/en, https://www.seoulviosys.com/en) and social media channels (LinkedIn).

About CRI (Color Rendering Index)

An indicator of how accurately a light source reproduces the colors of objects under natural sunlight. (For example, CRI 70: Designed so that the colors of 14 standard color samples match more than 70% of the colors seen under sunlight.)

View source version on businesswire.com: https://www.businesswire.com/news/home/20241225151382/en/

Contacts

Seoul Semiconductor Co., Ltd.
Jinseop Jung
jjs8732@seoulsemicon.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

TEVIMBRA Approved in U.S. for First-line Treatment of Gastric and Gastroesophageal Junction Cancers in Combination with Chemotherapy27.12.2024 13:00:00 EET | Press release

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced the U.S. Food and Drug Administration (FDA) has approved TEVIMBRA® (tislelizumab-jsgr), in combination with platinum and fluoropyrimidine-based chemotherapy, for the first-line treatment of unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma (G/GEJ) in adults whose tumors express PD-L1 (≥1). “Today’s FDA approval of TEVIMBRA for the treatment of gastric or gastroesophageal junction cancers in PD-L1 positive adult patients marks a significant step forward in our mission to deliver transformative therapies to patients with cancer,” said Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeiGene. “This is the second U.S. approval for TEVIMBRA this year, underscoring its potential to address critical needs in oncology. We remain deeply grateful to the patients, clinicians, and resear

Takeda Announces Approval of HYQVIA ® 10% S.C. (Subcutaneous) Injection Set in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia27.12.2024 08:00:00 EET | Press release

Takeda (TSE:4502/NYSE:TAK) today announced that the Japanese Ministry of Health, Labour and Welfare has approved the use of HYQVIA® [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] in patients with agammaglobulinemia or hypogammaglobulinemia1, disorders characterized by very low or absent levels of antibodies and an increased risk of serious recurring infection caused by primary immunodeficiency (PID) or secondary immunodeficiency (SID)2. The approval marks availability of the first and only facilitated subcutaneous immunoglobulin (fSCIG) therapy as a treatment option for appropriate patients in Japan. HYQVIA is the first plasma-derived therapy for subcutaneous injection in Japan that consists of a combination of one vial of Immunoglobulin 10% and one vial of Recombinant Human Hyaluronidase PH20 (rHuPH20). The administration of rHuPH20 increases the dispersion and absorption of immunoglobulin (IG) in the subcutaneous tissue, allowing larger volumes to be infu

Kolmar Korea Named One of the TIME’s World’s Best Companies for Sustainable Growth26.12.2024 16:00:00 EET | Press release

Kolmar Korea (KRX: 024720) has been recognized by TIME Magazine as one of the World’s Best Companies for Sustainable Growth 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241226863828/en/ Kolmar Korea on TIME's World's Best Companies in Sustainable Growth 2025 (Image: Kolmar Korea) On November 27, TIME, in collaboration with a global market research firm Statista, unveiled a list of the top 500 companies worldwide, demonstrating exceptional sustainable growth. Kolmar Korea took place 125th around the globe and 6th among Korean companies. Notably, it was the only Korean cosmetics company on the list, which featured a total of 23 Korean companies. The rankings were based on an evaluation of revenue growth, financial stability, and environmental impact, each contributing equally to a final score out of 100 points. TIME and Statista analyzed 3,000 major companies from 150 countries, focusing exclusively on those with trans

ispace-EUROPE and the Italian Space Agency (ASI) Sign Payload Services Agreement to Transport a Laser Retroreflector Array (LaRA2) on the Moon Surface26.12.2024 09:00:00 EET | Press release

ispace EUROPE S.A. (ispace-EUROPE), the Luxembourg-based subsidiary of ispace, inc., and the Italian Space Agency (ASI) have signed a payload services agreement to transport a Laser Retroreflector Array (LaRA2) to enable accurate position measurements on the Moon via laser ranging experiments, the two organizations announced today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241225137548/en/ The shape of LaRA2, a palm-sized dome (Photo: Business Wire) The agreement marks the first full-scale contract between ispace-EUROPE and ASI, with both organizations looking to joint future lunar development. LaRA2 is a small, robust, and lightweight instrument built to work without any power source and to survive the harsh surface conditions on the Moon for an extended period of time. It features a precise array of retroreflectors (corner cube prisms) designed to reflect laser beams directly back to their source, regardless of the an

Datopotamab Deruxtecan Application in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer Voluntarily Withdrawn24.12.2024 09:00:00 EET | Press release

Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN) have voluntarily withdrawn the marketing authorization application (MAA) in the EU for datopotamab deruxtecan (Dato-DXd) for the treatment of adult patients with locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) based on the TROPION-Lung01 phase 3 trial. The decision to withdraw the MAA was informed by feedback from the Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA). Daiichi Sankyo and AstraZeneca will continue to work to bring datopotamab deruxtecan to patients with lung cancer in the EU who can benefit and are committed to unlocking the potential of this medicine in lung cancer through our robust clinical development program which includes seven pivotal trials in various lung cancer settings. Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed by Dai

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye